SCHEMBL7128604

SCHEMBL7128604

CCN(Cc1ccccc1)Cc1cccc2c1C(S(=O)(=O)c1ccccc1)CS2(=O)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
RORC P51449 1/20 0.35
OPRM1 P35372 1/20 0.34
OPRK1 P41145 1/20 0.34
BCHE P06276 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
CNR2 P34972 1/20 0.33
DRD2 P14416 1/20 0.33
DRD3 P35462 1/20 0.33
ACHE P22303 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
LTA4H P09960 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7129712 0.99 KDM4E (0.36) KDM4ECYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL7131746 0.87 KDM4E (0.38) KDM4ECYP2D6RORCBCHEL3MBTL1
SCHEMBL7152940 0.84 HTR6 (0.36) KDM4EL3MBTL1DRD2DRD3CA1
SCHEMBL7127710 0.84 MAPT (0.35) L3MBTL1MAPK1CA1CA2CA9
Hydrochloric Acid SCHEMBL7163940 0.83 HTR6 (0.35) L3MBTL1DRD2DRD3MAPK1CA1
SCHEMBL7153689 0.83 SMN1; SMN2 (0.31)
SCHEMBL7131873 0.81 CHRM2 (0.34) KDM4EOPRM1OPRK1MAPK1
SCHEMBL7133949 0.81 ALDH1A1 (0.32) TSHR
SCHEMBL7132337 0.78 MAPT (0.35) L3MBTL1MAPK1CA1CA2CA9
SCHEMBL7243028 0.78 CA1 (0.35) CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient KONISHI MIKIO (JP) 2003-04-17 US claimed
US-6420391-B1 PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S ONO PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US claimed
EP-1067128-A1 FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient TPMT, CD47, THPO KDM4E 1111/4885CYP1A2 1294/4885CYP2D6 471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.